683 Capital Management’s AnaptysBio ANAB Stock Holding History

683 Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.6M	Buy	660,000 +35,000	+6%	+$2.12M	2.19%	9
2026 Q1	$34.7M	Sell	625,000 -23,093	-4%	-$1.24M	1.81%	15
2025 Q4	$31.4M	Buy	648,093 +101,093	+18%	+$3.94M	1.37%	15
2025 Q3	$16.7M	Buy	547,000 +47,000	+9%	+$1.08M	0.88%	30
2025 Q2	$11.1M	Buy	500,000 +304,373	+156%	+$6.37M	0.73%	39
2025 Q1	$3.64M	Buy	+195,627	New	+$3.26M	0.25%	88

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's ANAB Position: Q2 2026 in Review

683 Capital Management increased its AnaptysBio (ANAB) stake by 5.6% in Q2 2026, buying an estimated $2.12M and bringing the position to 660,000 shares worth $44.6M. The position accounts for 2.19% of the portfolio, ranked #9.

683 Capital Management first reported a position in ANAB in Q1 2025 and has held it in 6 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

683 Capital Management held 660,000 shares of AnaptysBio worth $44.6M as of Q2 2026.
683 Capital Management bought 35,000 AnaptysBio shares in Q2 2026, an estimated $2.12M.
AnaptysBio made up 2.19% of 683 Capital Management's portfolio in Q2 2026, its #9 holding.
683 Capital Management first reported a position in AnaptysBio in Q1 2025 and has held it in 6 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.